CoChat

Aromatase inhibitors in men: effects and therapeutic options

Open access
de Ronde, Willem, de Jong, Frank H · 2011 · Reproductive Biology and Endocrinology

The DOI matches its Crossref record; 93 of the 103 references it cites were found in a registry or an index; 7 of the 157 sources its claims cite were checked for support.

Abstract

Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men Therefore, aromatase inhibitors may be used to increase adult height in boys with gonadotropin-independent precocious puberty, idiopathic short stature and constitutional delay of puberty. Long-term efficacy and safety of the use of aromatase inhibitors has not yet been established in males, however, and their routine use is therefore not yet recommended.

Overview

CoChat Summary

TL;DR

Aromatase inhibitors lower estradiol in males and can raise gonadotropins/testosterone, delay epiphysial maturation in boys, and sometimes increase predicted adult height. The review concludes they are promising in selected settings but not yet recommended routinely because long-term efficacy and safety remain uncertain.

Key findings

  • In boys with idiopathic short stature treated with letrozole 2.5 mg once daily for 2 years, bone age progressed significantly more slowly and predicted adult height increased by 5.9 cm, while growth velocity was similar to placebo.
  • In boys with constitutional delay of puberty, testosterone plus letrozole increased growth velocity and slowed epiphysial maturation, leading to a significant increase in predicted adult height.
  • In older men, anastrozole 1 mg daily for 12 weeks doubled mean bioavailable testosterone; atamestane 100 mg once daily for 36 weeks increased total testosterone by 40%, but these studies did not show beneficial effects on muscle strength, body composition, or quality of life.
  • For gynecomastia, anastrozole 6 months did not significantly improve outcomes versus placebo in pubertal boys, and tamoxifen was reported to be much more effective than anastrozole for preventing gynecomastia in men receiving bicalutamide.

Methods

  • Narrative review of published evidence on aromatase inhibitors in males, covering boys and adult men, with discussion of case reports, uncontrolled studies, and controlled trials.
  • The paper summarizes specific clinical studies in settings including idiopathic short stature, constitutional delay of puberty, late-onset hypogonadism, obesity, gynecomastia, and male fertility.
  • Main analysis is qualitative synthesis of reported endocrine, skeletal, and clinical outcomes across studies, rather than a new original dataset.

Limitations

  • The paper states that long-term efficacy and safety have not yet been established in males, so routine use is not recommended.
  • The text makes evident that much of the evidence base is small, heterogeneous, and often uncontrolled (e.g., “three small studies,” case studies, and studies with relatively small numbers), which limits certainty.
  • The paper states that for older men, the testosterone-raising effect may be too weak, especially in those with the lowest baseline testosterone levels who might benefit most.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/1477-7827-9-93

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 5 Not valid · 76 Not checked · 31 Own results and interpretations

84 more claims

Create a free account to see all 112 claims and to verify the 18 references still open.

See all claims — free account
  • Probably not a substantial claim. 4
  • It may state two separate claims as one. 18
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 93 references

Cited by

See all 155

Metadata

Authors
de Ronde, W., & de Jong, F. H.
Venue
Reproductive Biology and Endocrinology
Published
2011
Volume
9
Issue
1
Pages
93
ISSN
1477-7827 (ISSN-L)
OpenAlex
W2104663096
Cited by
155
References
103
Citations by year
2026: 6 · 2025: 14 · 2024: 10 · 2023: 18 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 12 · 2018: 6 · 2017: 21 · 2016: 9 · 2015: 16 · 2014: 8 · 2013: 3 · 2012: 3
FWCI
0.69
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Reproductive Biology and Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
aromatase inhibitors, male patients, precocious puberty, idiopathic short stature, constitutional delay of growth and puberty, adult height, testosterone levels, long-term efficacy and safety
MeSH terms
Adolescent, Body Height, Bone Development, Breast, Child, Growth Disorders, Humans, Male, Obesity, Puberty, Puberty, Precocious, Spermatogenesis, Testosterone, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aromatase inhibitors in men: effects and therapeutic options. https://app.cochat.ai/papers/10.1186/1477-7827-9-93
The paper
de Ronde, W., & de Jong, F. H. (2011). Aromatase inhibitors in men: effects and therapeutic options. Reproductive Biology and Endocrinology. https://doi.org/10.1186/1477-7827-9-93

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.